+1 more
Terpenoid+1 more
Cannabinoid systemΔ9-THC, Δ8-THC, THCP +3 moreΔ9-THC, Δ8-THC, THCP, THCV, THCH, synthetic cannabinoids show less
Tetrahydrocannabutol
THCB (Δ9-tetrahydrocannabutol) is a cannabinoid of the dibenzopyran class. It is a direct structural relative of Δ9-THC, differing only in a slightly shorter side chain. THCB activates cannabinoid receptors in the brain, but only partially — producing a lower ceiling on intoxication than THC.[1]
THCB (Δ9-tetrahydrocannabutol) is a naturally-occurring cannabinoid of the dibenzopyran class. It is a direct homolog of Δ9-THC, with a shorter four-carbon side chain. THCB is a partial CB1 agonist, producing its effects by activating cannabinoid signaling with a lower ceiling on intensity than THC.[1]
+1 more
Terpenoid+1 more
Cannabinoid systemΔ9-THC, Δ8-THC, THCP +3 moreΔ9-THC, Δ8-THC, THCP, THCV, THCH, synthetic cannabinoids show less
THCB was first isolated in 2020 from pharmaceutical-grade Italian cannabis.[1] Since 2021, products labeled THCB have appeared on unregulated consumer markets, riding the wave of designer THC analogs sold in jurisdictions where Δ9-THC is controlled.[2] It circulates today in vape cartridges, edibles, and oils — largely outside pharmaceutical oversight.[3]
Subjective effects include euphoria, relaxation, altered perception, and mild sedation. The experience is described as similar to THC but with a clearer headspace and less cognitive fog, particularly at lower doses.[3] At higher doses, anxiety, paranoia, and disorientation are common.
No dependence data exist for THCB; by class analogy with THC, regular use is expected to carry mild-to-moderate dependence risk.[4] The more immediate risk comes from product quality — unregulated THCB contains unlabeled isomers and synthesis byproducts whose safety profiles are entirely unknown.[2] THCB has never been studied in humans; what is known rests on a single isolation study, mouse data, and structural analogy to THC.
History[edit]
Discovery
THCB was first isolated in 2020 by Linciano, Citti, and colleagues from FM2, a pharmaceutical-grade Italian cannabis cultivar.[1] The compound was identified through mass spectrometry screening of minor cannabinoid fractions and confirmed by stereoselective synthesis.[1] The same research effort also uncovered THCP and THCH, completing the natural THC homolog series from C3 to C7.[5][6]
Scientific significance
The discovery showed that THCB's cannabinoid receptor affinity is comparable to THC, while the longer-chain THCP proved far more potent.[1][5] In mice, THCB produced analgesic and anti-inflammatory effects alongside typical cannabinoid responses — but only partially, establishing it as a partial agonist rather than a full one.[1]
Commercial emergence
Since approximately 2021, both Δ8-THCB and Δ9-THCB have appeared in internet-sold vape cartridges, edibles, and oils.[2] Forensic analysis in Japan confirmed both isomers in consumer products alongside Δ11-THCB as a synthesis byproduct.[2] THCB's trajectory follows the wider designer THC market — novel homologs sold in jurisdictions where Δ9-THC remains controlled.[3]
The name "tetrahydrocannabutol" reflects its structure: "cannabu-" derives from "butyl," the four-carbon chain. THC-C4 appears in older chemical literature, and the abbreviations THCB and THC-B are used interchangeably in commercial and scientific contexts. A CAS registry number (60008-00-6) predates the 2020 isolation, suggesting the compound was catalogued — possibly from synthetic work — before its identification as a natural phytocannabinoid.citation needed
Chemistry[edit]
Structural class
THCB belongs to the dibenzopyran cannabinoid family — the same three-ring scaffold shared by THC, THCV, and all classical phytocannabinoids. What distinguishes it is a four-carbon (butyl) side chain, one unit shorter than THC's five-carbon chain and one unit longer than THCV's three-carbon chain. Research on THC analogs established that side chains in the C4–C8 range support strong cannabinoid receptor binding.[7]
| Molecular formula | C₂₀H₂₈O₂ |
| Molecular weight | 300.4 g/mol |
The molecular formula is one CH₂ unit smaller than Δ9-THC (C₂₁H₃₀O₂, 314.5 g/mol).
Natural occurrence
THCB occurs at trace concentrations in Cannabis sativa, arising from the same biosynthetic pathway as THC but starting from a shorter fatty acid precursor.[8][9] It was first isolated from the Italian FM2 pharmaceutical cultivar.[1] Natural concentrations are far below those of THC or CBD.
Pharmacology[edit]
Mechanism of action
THCB acts as a partial agonist at CB1 receptors — the primary driver of cannabinoid psychoactivity.[1][5] It also binds CB2 receptors, though with lower affinity.[1] Partial agonism creates a ceiling: no matter the dose, THCB cannot activate CB1 to the same degree as THC.
In mice, THCB produced pain suppression and reduced inflammation alongside the typical cannabinoid responses.[1] Separate research suggests its analgesic activity may extend beyond CB1 and CB2 signaling.[10]
Pharmacokinetics
No pharmacokinetic data exist for THCB. By analogy with THC, inhaled cannabinoids reach peak blood levels within roughly 10 minutes;[11][12] oral forms take 1–6 hours and absorb much less reliably.[11] THC is highly fat-soluble, distributes widely, and clears slowly — liver enzymes break it down in stages, and metabolites persist for weeks in regular users.[12][13][14] THCB is expected to follow the same pattern, but this has not been confirmed.inferred
All pharmacokinetic parameters above are derived from Δ9-THC data by structural analogy. No published ADME studies for THCB exist.
Neuroscience[edit]
Where it acts
CB1 receptors are concentrated in brain regions governing memory (hippocampus), movement (basal ganglia and cerebellum), and decision-making (prefrontal cortex).[12] As a partial CB1 agonist, THCB activates signaling in these areas — but less forcefully than THC.
Partial agonism predicts less memory disruption, less motor suppression, and weaker activation of the brain's reward circuits — consistent with user descriptions of a "clear-headed" quality and potentially lower compulsive-use liability.[1]
Why it matters
The endocannabinoid system acts as a homeostatic balancer of neural activity throughout the brain. Partial agonists like THCB may enhance signaling when it is naturally low, while competing with the brain's own cannabinoids when it is already high. Whether this translates to therapeutic benefits or reduced abuse potential has not been tested directly.
Key unknowns include whether THCB produces measurably less memory suppression than THC at equivalent doses, whether it drives neuroplasticity changes, and whether combining it with THC could blunt THC's effects at CB1 at certain concentration ratios.
Subjective Effects[edit]
THCB delivers a cannabis-like experience — lighter than THC and less cognitively demanding. The partial CB1 agonism sets a ceiling on peak intoxication, which may account for the "clear-headed" quality users consistently describe: the experience feels functional rather than overwhelming.[3]
Compared to Δ9-THC, the character is similar but the intensity is blunted. Compared to THCV, which can dampen cannabinoid effects at lower doses, THCB sits closer to the THC end of the spectrum. No controlled studies have evaluated THCB's subjective effects; all characterizations come from user reports.[3]
THCB was first isolated in 2020 by researchers at the University of Modena from pharmaceutical-grade Italian cannabis, part of a systematic effort that mapped the full THC homolog series from C3 to C7.[1][2][3] Since approximately 2021, products containing both Δ8-THCB and Δ9-THCB have appeared on unregulated consumer markets as part of the broader designer THC expansion.[4][5] It circulates in e-cigarette cartridges, edibles, and oils, primarily in jurisdictions where Δ9-THC remains controlled.
Subjective effects include euphoria, relaxation, altered perception, and mild sedation. The experience is described as qualitatively similar to THC but with a reportedly clearer headspace and less cognitive weight, particularly at lower doses.[5] Anxiety, paranoia, disorientation, and excessive intoxication at higher doses are common unsought effects.
No dependence data exist; by class analogy with THC, mild-to-moderate cannabis-type dependence with chronic use is expected.[6] The primary acute risk lies in product variability — unregulated products may contain Δ8-THCB isomers and synthesis byproducts like Δ11-THCB whose safety profiles are entirely unknown.[4] No controlled human studies have been conducted; the current understanding rests on a single isolation study, mouse data, and structural analogy to THC.
History[edit]
Discovery
THCB was first isolated and characterized in 2020 by Linciano, Citti, and colleagues at the University of Modena and Reggio Emilia.[1] The source material was FM2, an Italian pharmaceutical-grade Cannabis sativa cultivar produced by the Military Chemical Pharmaceutical Institute in Florence. The compound was identified through high-resolution mass spectrometry screening of minor cannabinoid fractions and confirmed by stereoselective synthesis.[1] This work was part of a broader effort that also uncovered THCP (C7 chain)[2] and THCH (C6 chain),[3] completing the natural phytocannabinoid homolog series from C3 to C7.
Scientific significance
The discovery of THCB filled in one position of the THC alkyl chain series — a systematic map of how side-chain length affects cannabinoid receptor binding. Binding assays showed THCB's CB1 affinity was comparable to THC itself, while the longer-chain THCP proved far more potent.[1][2] In mice, THCB produced analgesic and anti-inflammatory effects but only a partial cannabinoid response, establishing it as a partial agonist rather than a full one.[1]
Commercial emergence
Since approximately 2021, both Δ8-THCB and Δ9-THCB have appeared in internet-sold e-cigarette cartridges, edibles, and oils.[4] Forensic analyses in Japan confirmed both isomers in commercial products between 2022 and 2023, along with Δ11-THCB as a synthesis byproduct.[4] THCB's commercial trajectory parallels the wider designer THC market, in which novel homologs and isomers are sold in jurisdictions where Δ9-THC remains controlled.[5]
The name "tetrahydrocannabutol" follows systematic cannabinoid nomenclature: "cannabu-" derives from "butyl," denoting the four-carbon side chain, while the rest mirrors tetrahydrocannabinol. The abbreviations THCB and THC-B are used interchangeably in commercial and scientific contexts; THC-C4 appears in older chemical literature. A CAS registry number (60008-00-6) predating the 2020 isolation suggests the compound was catalogued — possibly from synthetic work — before its identification as a natural phytocannabinoid. Roger Adams' group synthesized THC analogs with varied chain lengths in the 1940s, though a specific butyl-chain study claimed by secondary sources could not be confirmed from primary literature.citation needed
Chemistry[edit]
Structural class
THCB belongs to the dibenzopyran cannabinoid family — the same tricyclic scaffold shared by THC, THCV, and all classical phytocannabinoids. The skeleton consists of a phenol ring, a pyran ring, and a cyclohexene ring. What distinguishes THCB is the four-carbon (butyl) chain at C-3, one methylene unit shorter than THC's five-carbon (pentyl) chain and one unit longer than THCV's three-carbon (propyl) chain. Structure-activity studies on THC analogs established that side chains in the C4–C8 range support strong CB1 binding.[7]
| Molecular formula | C₂₀H₂₈O₂ |
| Molecular weight | 300.4 g/mol |
The molecular formula reflects one CH₂ unit fewer than Δ9-THC (C₂₁H₃₀O₂, 314.5 g/mol).
Stereochemistry
THCB contains two chirality centers at C-6a and C-10a, adopting the (6aR,10aR) configuration in the naturally occurring (−)-trans form — identical to natural Δ9-THC.[1] The structure was confirmed through stereoselective synthesis achieving 91% yield, with absolute configuration verified by electronic circular dichroism.[1]
Both Δ8-THCB and Δ9-THCB positional isomers exist in commercial products — they differ in the position of a double bond within the cyclohexene ring.[4]
Natural occurrence
THCB occurs at trace concentrations in Cannabis sativa, arising from the same biosynthetic pathway as THC but with a butyric acid (C4) starter unit rather than the hexanoic acid (C6) that feeds the THC/CBD pathway.[8][9] It was first isolated from the Italian FM2 pharmaceutical cultivar.[1] Natural concentrations are far below those of THC or CBD.
Pharmacology[edit]
Mechanism of action
THCB acts as a partial agonist at the CB1, the primary mediator of cannabinoid psychoactivity.[1] It also binds the CB2, though with lower affinity.[1] Both affinities are described as comparable to Δ9-THC under the same assay conditions.[1][2]
The distinction between partial and full agonism is functionally important. In mice, THCB produced reduced locomotion, catalepsy, pain suppression, and temperature drop — the standard cannabinoid test battery — but without the full intensity seen with reference compounds.[1] This contrasts with the longer-chain homolog THCP, which produced a complete response consistent with full agonism.[2] The practical implication: at any dose, THCB reaches a ceiling on CB1-mediated effects that full agonists do not.
THCB also showed both analgesic and anti-inflammatory activity in the formalin pain model in mice, reducing both acute neurogenic and delayed inflammatory pain responses.[1] Anand and colleagues tested THCB among minor cannabinoids in an in vitro model of nerve pain hypersensitivity, suggesting analgesic activity beyond the CB1/CB2 axis.[10]
Cannabinoids as a class can interact with multiple non-CB receptor targets including TRPV1, GPR55, and GABA-A receptors.[11] No THCB-specific data on any of these targets have been published.inferred
Pharmacokinetics
No pharmacokinetic data exist for THCB in any species. All parameters below are inferred from Δ9-THC by structural analogy.
When inhaled, THC reaches peak blood concentrations within roughly 10 minutes, with approximately 25–30% of the dose reaching the bloodstream.[12][13] Oral absorption is much lower (4–12%) and highly variable, with peak effects delayed 1–6 hours due to first-pass liver metabolism that generates an active metabolite.[12][13]
THC is highly fat-soluble and distributes widely throughout the body, with fat tissue serving as a long-term reservoir.[13] Liver enzymes break it down first to an active metabolite, then to an inactive one.[14][15] Metabolites persist for weeks in regular users, and the effective half-life is approximately 20–30 hours due to slow redistribution from fat stores.[12] THCB's shorter side chain would be expected to undergo analogous metabolism, but this has not been confirmed.inferred
All pharmacokinetic parameters above are derived from Δ9-THC data by structural analogy. No published ADME studies for THCB exist.
Neuroscience[edit]
Where it acts
CB1 receptors are concentrated in the hippocampus, basal ganglia, cerebellum, and prefrontal cortex. As a partial CB1 agonist, THCB modulates retrograde endocannabinoid signaling — the system by which neurons fine-tune neurotransmitter release at synapses throughout the brain.[13]
Partial agonism predicts reduced maximal disruption in each region: less memory suppression in the hippocampus, less motor suppression in the basal ganglia and cerebellum, and attenuated reward signaling in the mesolimbic pathway — consistent with user descriptions of a "clear-headed" quality and potentially lower compulsive-use liability.[1]
Why it matters
THCB is best understood not as a simple CB1 "activator" but as a modulator of endocannabinoid tone. The endocannabinoid system functions as a homeostatic regulator of neural excitability — exogenous partial agonists may augment signaling in low-tone states while competing with the body's own cannabinoids in high-tone states.
This framework, analogous to partial agonist pharmacology in other receptor systems, has implications for both the therapeutic ceiling and the reduced abuse potential theorized for THCB, though neither has been tested directly.
Key unknowns include whether THCB produces measurably less memory impairment than THC at equivalent doses in humans, whether it drives neuroplasticity (and to what degree partial agonism attenuates this), and whether co-administration with THC produces competitive antagonism at CB1 — effectively blunting THC's effects at certain concentration ratios.
Subjective Effects[edit]
The subjective character of THCB has not been evaluated in any controlled study. User reports describe a cannabinoid experience qualitatively similar to Δ9-THC — relaxation, mild euphoria, altered perception — but with a reportedly "clear-headed" quality and less cognitive fog, particularly at lower doses.[5] The partial CB1 agonist pharmacology predicts a lower ceiling on peak intoxication, which may underlie descriptions of a more functional, less impairing experience. Set, setting, and individual cannabinoid tolerance significantly shape the outcome.
Relative to THC, THCB occupies a position of comparable receptor affinity but reduced maximal effect — pharmacologically analogous to the relationship between buprenorphine and morphine in the opioid system. Compared to THCV, which shows mixed agonist-antagonist properties at CB1, THCB sits closer to the THC end of the cannabinoid spectrum. Product variability — including the presence of Δ8-THCB isomers and uncharacterized synthesis byproducts — introduces an additional unpredictable variable absent from pharmaceutical-grade cannabinoids.
Effect Grid
Noticeable euphoria, relaxation, and analgesia define the common dose range. Sensory enhancement becomes more apparent — music enhancement, color enhancement, and taste enhancement are typical. Time alteration manifests as subjective slowing. Thought deceleration and mild thought connectivity may emerge.
Physically, body high and muscle relaxation are prominent. Dry mouth is expected. Mild motor control impairment and dizziness may occur. Appetite enhancement is common. The partial CB1 agonist ceiling begins to manifest — effects plateau rather than escalating linearly with dose.
This is a full but manageable cannabinoid experience. Expect 4–8 hours of effects via oral ingestion. Driving and operating machinery are unsafe.
Modeled from the effect's dose-dependence curve — not per-substance measurements.
Dreaming suppression · Sound sensitivity · Spatial disorientation · Taste enhancement · Touch enhancement · Olfactory enhancement · Auditory distortion · Brightness alteration · Depth perception distortion · Light sensitivity · Perspective distortion · Proprioceptive distortion · Vestibular distortion · Visual acuity suppression · Visual haze / noise · Sleep-transition hallucinations · Peripheral misidentification · Peripheral vision distortion · Tinnitus · Tracers · Visual breathing · Visual drifting · Geometry · Visual morphing · Visual processing suppression · Auditory hallucinations · External hallucinations · Internal hallucinations
Touch enhancement · Olfactory enhancement · Auditory distortion · Brightness alteration · Depth perception distortion · Light sensitivity · Perspective distortion · Proprioceptive distortion · Vestibular distortion · Visual acuity suppression · Visual haze / noise · Sleep-transition hallucinations · Peripheral misidentification · Peripheral vision distortion · Tinnitus · Tracers · Visual breathing · Visual drifting · Geometry · Visual morphing · Visual processing suppression · Auditory hallucinations · External hallucinations · Internal hallucinations
Appetite enhancement · Body scan awareness · Bodily heaviness · Heart rate perception changes · Laughter fits · Muscle relaxation · Dehydration sensation · Pain suppression · Physical fatigue · Spontaneous body sensations · Tactile euphoria · Dizziness · Nausea suppression · Sexual arousal enhancement · Watery eyes · Nausea · Bodily pressures · Body schema distortion · Breathing alteration · Constipation · Headache · Restlessness · Stimulation · Temperature dysregulation · Tingling / electric sensations · Vibrations / buzzing · Nystagmus (eye wobbles) · Trembling · Vomiting · Bodily dissociation
Heart rate perception changes · Laughter fits · Muscle relaxation · Dehydration sensation · Pain suppression · Physical fatigue · Spontaneous body sensations · Tactile euphoria · Dizziness · Nausea suppression · Sexual arousal enhancement · Watery eyes · Nausea · Bodily pressures · Body schema distortion · Breathing alteration · Constipation · Headache · Restlessness · Stimulation · Tingling / electric sensations · Vibrations / buzzing · Nystagmus (eye wobbles) · Trembling · Vomiting · Bodily dissociation
Aesthetic enhancement · Cognitive euphoria · Focus suppression · Immersion enhancement · Memory fragmentation · Novelty enhancement · Thought connectivity · Humor enhancement · Analysis suppression · Cognitive fatigue · Conceptual thinking · Creativity enhancement · Information processing suppression · Introspection enhancement · Motivation suppression · Openness enhancement · Cognitive dysphoria · Cognitive flexibility · Confusion · Thought loops · Increased nature relatedness · Language suppression · Multiple thought streams · Pattern recognition enhancement · Suggestibility enhancement · Thought deceleration · Analysis enhancement · Delusions of sobriety · Thought acceleration · Focus enhancement · Information processing enhancement · Language enhancement · Motivation enhancement · Amnesia · Delusions
Immersion enhancement · Memory fragmentation · Novelty enhancement · Thought connectivity · Humor enhancement · Analysis suppression · Cognitive fatigue · Conceptual thinking · Creativity enhancement · Information processing suppression · Introspection enhancement · Motivation suppression · Openness enhancement · Cognitive dysphoria · Cognitive flexibility · Confusion · Thought loops · Increased nature relatedness · Language suppression · Multiple thought streams · Pattern recognition enhancement · Thought deceleration · Analysis enhancement · Delusions of sobriety · Thought acceleration · Focus enhancement · Information processing enhancement · Language enhancement · Motivation enhancement · Amnesia · Delusions
Anxiety suppression · Dysphoria · Emotional lability · Empathy enhancement · Simultaneous emotions · Catharsis · Irritability
Simultaneous emotions · Catharsis · Irritability
Sociability enhancement · Communication suppression · Depersonalization · Disinhibition · Social connection · Flow state · Compulsive behavior reduction · Ego inflation · Sociability suppression · Social disconnection · Trust enhancement · Communication enhancement · Cognitive disconnection · Boundary dissolution · Identity alteration · Ego dissolution
Social connection · Flow state · Compulsive behavior reduction · Ego inflation · Sociability suppression · Social disconnection · Trust enhancement · Communication enhancement · Cognitive disconnection · Boundary dissolution · Identity alteration · Ego dissolution
Timeline
Gradual, barely perceptible shift in body awareness. THCB is described as a 'creeper' — onset is slower than expected for a cannabinoid edible.
Progressive intensification of body relaxation and mood elevation. Mild sensory enhancement begins to register.
Maximum effect expression — euphoria, body high, analgesia, and sensory enhancement. Time alteration and thought deceleration are characteristic. Partial agonist ceiling may limit peak intensity relative to equivalent THC doses.
Gradual diminution of psychoactive effects. Sedation often increases as euphoria fades. Appetite enhancement may persist.
Residual relaxation and mild cognitive fog. Mood may remain subtly elevated.
⚠ Do not drive or operate heavy machinery for at least 6 hours after oral ingestion, or longer if residual effects are noticed.
Safety[edit]
- Acute toxicity
- Low
- Chronic toxicity
- Low
- Withdrawal
- Mild
- Tolerance buildup
- moderate
- Tolerance reset
- 21 days
- Physical
- Low
- Psychological
- Low
- Compulsive redosing
- Low
- Dose escalation
- Moderate
- Cross-tol.
- Δ9-THC · Δ8-THC · THCP
Toxicity
No lethal dose, therapeutic index, or controlled toxicity data exist for THCB.safety citation needed By class analogy with THC, active doses can increase heart rate, drop blood pressure, impair thinking and coordination, and produce anxiety or paranoia.[12]inferred THCB's partial agonist status may limit the maximum severity of these effects, but this has not been tested.
Synthesis byproducts
Forensic analysis of commercial Δ8-THCB products has identified Δ11-THCB as a byproduct of manufacture.[2] Its safety profile is entirely unknown. Unregulated products may contain variable amounts of this and other uncharacterized impurities.
Drug testing
A validated laboratory method can detect THCB in blood and urine.[15] Standard cannabis screens detect THC metabolites; whether THCB metabolites trigger these tests has not been directly studied, but is considered likely given structural similarity.inferred
Psychological risks
Higher doses raise the risk of anxiety, paranoia, and disorientation — more common in inexperienced users.[3] People with a personal or family history of psychotic illness — schizophrenia, bipolar disorder — face a heightened risk: CB1 agonism can trigger or worsen psychotic episodes.[12]
Short-term memory disruption, thought deceleration, and impaired executive function are characteristic of CB1 activation. Duration and severity from THCB are unknown. Feelings of unreality and disconnection from self are possible at higher doses, by class analogy with THC.
Tolerance and dependence
With repeated high-dose use, CB1 receptors reduce their sensitivity — tolerance builds, and more of the substance is needed for the same effect.[4] THC-tolerant individuals would likely find THCB's effects reduced from the start, since cross-tolerance between CB1 agonists is well-established.[4] As a partial agonist, THCB may produce less tolerance and dependence than full agonists, but this has not been tested at CB1.
Stopping regular use can bring irritability, insomnia, anxiety, and appetite changes — the cannabis withdrawal pattern.[16][12] No approved medications exist for cannabis use disorder; behavioral therapy is first-line.[16]
Drug Interactions
No interaction studies have been conducted on THCB. All interactions below are predicted from Δ9-THC by structural analogy.safety citation needed
Metabolic interactions
THC and its analogs slow the liver enzymes that break down many common medications, causing those drugs to build up to higher levels in the blood.[14][17] THCB is predicted to share this profile. Clinically relevant interactions include:
- Blood thinners: Warfarin (increased bleeding risk), diclofenac, phenytoin
- Medications processed by CYP3A4: midazolam, tacrolimus, cyclosporine, some HIV medications, some statins
- Bupropion and cyclophosphamide
Additive effects
Combining THCB with alcohol, benzodiazepines, opioids, or other cannabinoids adds to sedation and impairment.[12] Combining with stimulants — amphetamines or cocaine — is expected to push heart rate and blood pressure higher.
Contraindications
7 knownNo THCB-specific contraindication data exist. The following are inferred from the CB1 agonist drug classsafety citation needed:
- Psychotic disorders — schizophrenia, schizoaffective disorder, bipolar disorder with psychotic features. CB1 agonism can trigger or worsen psychotic episodes.
- Family history of psychotic disorders — elevated genetic risk for cannabinoid-precipitated psychosis.
- Pregnancy and breastfeeding — cannabinoids cross the placenta and enter breast milk; THC is associated with reduced fetal growth and neurodevelopmental effects.[12]
- Unstable heart conditions — increased heart rate and blood pressure changes from CB1 activation may be dangerous in people with irregular heartbeat, recent heart attack, or heart failure.
- Anticoagulant therapy — predicted enzyme inhibition could increase the effect of warfarin and similar blood thinners.[17]
- Narrow-therapeutic-index medications — tacrolimus, cyclosporine, certain anti-seizure medications.[12][17]
- Liver impairment — if THCB is metabolized in the liver like THC, impaired liver function would reduce clearance and prolong effects.
Harm Reduction[edit]
Forms & Identification
THCB products enter the market without pharmaceutical oversight. What is sold as "THCB" may contain a mixture of Δ8-THCB, Δ9-THCB, and synthesis byproducts including Δ11-THCB.[2] Standard cannabinoid reagent tests cannot reliably distinguish between THC homologs.
Laboratory testing (LC-MS/MS) is the only reliable method to confirm what a product actually contains.[15] Certificates of analysis from third-party labs should be verified directly with the testing laboratory — COAs are easily fabricated.
Guidelines
- Start low. No controlled dose-response data exist for THCB. Begin well below the dose used for familiar THC products and wait for full onset before redosing.
- Test the product. Request and verify third-party laboratory analysis. Reject products without credible certificates of analysis.
- Time the onset. Oral products likely follow the same delayed onset as THC edibles — effects may take 1–2 hours to appear. Do not redose during this window.
- Avoid mixing. Combining with alcohol, other cannabinoids, or sedatives increases impairment unpredictably.
- Secure the environment. Do not drive or operate machinery. Have a sober companion available, especially for early experiences.
Set & Setting
Psychological state and environment shape the experience, as with all cannabinoids. The partial agonist ceiling does not eliminate the risk of anxiety or paranoia, particularly at higher doses. A calm, familiar setting with trusted company reduces the likelihood of an adverse reaction.
Aftercare & integration. Uncomfortable THCB experiences generally resolve within hours. Hydration, light food, and rest support recovery. If anxiety or paranoia were prominent, time in a calm environment and talking through the experience with a trusted person can help normalize the response.
Persistent anxiety, depersonalization, or mood changes lasting more than 48 hours after use warrant professional consultation. These reactions are uncommon with cannabinoids but are documented following high-dose or adverse experiences.
Recovery & Support
Cannabis-type dependence — irritability, insomnia, appetite changes, restlessness upon stopping — is possible with regular THCB use.[16] The partial agonist profile may reduce but does not eliminate this risk.
Gradual tapering is generally better tolerated than stopping abruptly. No approved medications exist for cannabis use disorder; cognitive-behavioral therapy and motivational enhancement therapy are best-supported.[16] SAMHSA's National Helpline (1-800-662-4357) provides free referrals.
Recovery resources, crisis lines, and support pathways → View all
Emergency Response
Recognizing an emergency: Most adverse THCB experiences involve uncomfortable but self-limiting anxiety and paranoia. Seek immediate help if the person shows signs of psychosis (loss of contact with reality, severe agitation, self-harm risk), chest pain, fainting, or seizure.
Immediate steps:
- Call emergency services if the person is unresponsive, seizing, experiencing chest pain, or at risk of harming themselves or others.
- Move the person to a quiet, safe space. Reduce stimulation.
- Reassure them calmly. Remind them the effects are temporary and caused by a substance.
- Do not leave them alone.
- Do not induce vomiting if the product was ingested orally.
What to tell the dispatcher: Name the substance (THCB / THC structural analog), estimated amount and time of use, current symptoms, and any other substances consumed. Good Samaritan laws in many jurisdictions protect callers from prosecution.
Legal Status[edit]
Δ9-Tetrahydrocannabutol is not specifically listed under the United Nations Convention on Psychotropic Substances,[18] though several jurisdictions control it under generic definitions that cover THC alkyl homologs.[3]
| Jurisdiction | Classification | Key provisions |
|---|---|---|
| United Kingdom | Class B (controlled) | Covered under MDA 1971 generic text for THC alkyl homologs. ACMD confirmed in 2025 that THCB falls within existing Class B controls[19] |
| Czech Republic | Prohibited | Explicitly added to the prohibited substance list in July 2024citation needed |
| France | Controlled | Covered under ban on cannabinoids with benzo[c]chromene-type chemical nucleuscitation needed |
| Australia | Likely Schedule 8 (controlled) | Poisons Standard defines controlled tetrahydrocannabinols to include all alkyl homologs; THCB would fall within this definition[18]citation needed |
| United States | Legal grey area | Not explicitly scheduled under the CSA. Hemp-derived THCB may be argued as legal under the 2018 Farm Bill, but the DEA's position that synthetically derived tetrahydrocannabinols remain Schedule I creates significant uncertainty for semi-synthetic products. The Federal Analogue Act may apply if intended for human consumption |
| Canada | Not explicitly scheduled | CDSA Schedule II covers cannabis, THC, and analogs; potential analog liability as a THC homolog |
| Japan | Under monitoring | Forensic identification of THCB in consumer products documented since 2022[2] |
Legal status for novel cannabinoids changes rapidly. This information reflects publicly available sources and is not legal advice. Verify current status in the relevant jurisdiction before acting on it.
Safety[edit]
- Acute toxicity
- Low
- Chronic toxicity
- Low
- Withdrawal
- Mild
- Tolerance buildup
- moderate
- Tolerance reset
- 21 days
- Physical
- Low
- Psychological
- Low
- Compulsive redosing
- Low
- Dose escalation
- Moderate
- Cross-tol.
- Δ9-THC · Δ8-THC · THCP
Toxicity
No lethal dose, therapeutic index, or controlled toxicity data exist for THCB in any species.safety citation needed No adverse event case reports specific to THCB have been located in medical or forensic databases. The safety profile is entirely uncharacterized by controlled study.
By class analogy with Δ9-THC, expected adverse effects at active doses include increased heart rate, low blood pressure, impaired thinking, impaired coordination, anxiety, and paranoia.[13]inferred THCB's partial agonist status may limit the maximum severity of these effects, but this has not been tested.
Synthesis byproducts
Forensic analysis of internet-sold Δ8-THCB products has identified Δ11-THCB as a minor byproduct of the manufacturing process.[4] The safety profile of Δ11-THCB is entirely unknown. Unregulated products may contain variable amounts of this and other uncharacterized impurities.
Drug testing
A validated laboratory method can identify THCB in blood and urine.[16] Standard cannabis drug screens detect THC metabolites; whether THCB metabolites trigger these tests has not been directly studied but is considered likely given structural similarity.inferred
Psychological risks
No controlled data on psychological adverse effects exist. By class analogy with CB1 agonists:
- Anxiety and paranoia are dose-dependent, more common at higher doses and in inexperienced users.[5]
- Psychosis precipitation is a recognized risk in individuals with pre-existing vulnerability — schizophrenia spectrum disorders, bipolar disorder, or first-degree family history of psychotic illness.[13]
- Cognitive impairment — disrupted short-term memory, slowed processing, and impaired executive function — is characteristic of CB1 activation. Duration and severity from THCB are unknown.
- Depersonalization and derealization are reported with THC at higher doses and expected with THCB by class analogy.
Tolerance and dependence
No THCB-specific tolerance or dependence data exist. By class analogy with Δ9-THC, repeated high-dose use is expected to produce tolerance through CB1 receptor downregulation and desensitization.[6] Cross-tolerance between THC and other CB1 agonists is well-established — THC-tolerant individuals would be expected to show reduced response to THCB.[6]
As a partial agonist, THCB may theoretically produce less tolerance and dependence than full agonists — a pattern seen with partial agonists at other receptor systems. Whether this applies at CB1 has not been studied.
A cannabis-type withdrawal (irritability, insomnia, anxiety, appetite changes, restlessness) is documented for chronic high-dose THC use.[17][13] No approved medications exist for cannabis use disorder; behavioral interventions are first-line.[17] Whether chronic THCB use produces comparable withdrawal is unknown.
Drug Interactions
No THCB-specific interaction studies have been conducted. All interactions below are predicted from Δ9-THC by structural analogy.safety citation needed
Metabolic interactions
THC and its analogs interfere with liver enzymes responsible for metabolizing many common medications.[15][18] THCB is predicted to share this profile. Clinically relevant interactions include:
- Blood thinners: Warfarin (increased bleeding risk), diclofenac, phenytoin
- Medications processed by CYP3A4: midazolam, tacrolimus, cyclosporine, some HIV medications, some statins
- Bupropion and cyclophosphamide
Additive effects
Additive sedation and impairment are expected with alcohol, benzodiazepines, opioids, and other cannabinoids.[13] Additive heart rate and blood pressure increases are expected with stimulants (amphetamines, cocaine).
Contraindications
7 knownNo THCB-specific contraindication data exist. The following are inferred from the CB1 agonist drug classsafety citation needed:
- Psychotic disorders — schizophrenia, schizoaffective disorder, bipolar disorder with psychotic features. CB1 agonism can trigger or worsen psychotic episodes.
- Family history of psychotic disorders — elevated genetic risk for cannabinoid-precipitated psychosis.
- Pregnancy and breastfeeding — cannabinoids cross the placenta and enter breast milk; THC is associated with reduced fetal growth and neurodevelopmental effects.[13]
- Unstable heart conditions — increased heart rate and blood pressure changes from CB1 activation may be dangerous in people with irregular heartbeat, recent heart attack, or heart failure.
- Anticoagulant therapy — predicted enzyme inhibition could increase the effect of warfarin and similar blood thinners.[18]
- Narrow-therapeutic-index medications — tacrolimus, cyclosporine, certain anti-seizure medications.[13][18]
- Liver impairment — if THCB is metabolized in the liver like THC, impaired liver function would reduce clearance and prolong effects.
Harm Reduction[edit]
Forms & Identification
THCB products enter the market without pharmaceutical oversight, and what is sold as "THCB" may be a mixture of Δ8-THCB, Δ9-THCB, and synthesis byproducts including Δ11-THCB.[4] Standard cannabinoid reagent tests do not reliably distinguish between THC homologs. Laboratory testing (LC-MS/MS) is the only reliable method to confirm product identity and purity.[16] Certificates of analysis from third-party labs should be verified directly with the laboratory — COAs are easily fabricated.
Guidelines
- Start low. No controlled dose-response data exist for THCB. Begin well below the dose you would use for familiar THC products and wait for full onset before redosing.
- Test your product. Request and verify third-party laboratory analysis. Reject products without credible certificates of analysis.
- Time your onset. Oral THCB products (edibles, oils) likely follow the same delayed onset pattern as THC edibles — effects may take 1–2 hours to appear. Do not redose during this window.
- Avoid mixing. Combining with alcohol, other cannabinoids, or sedatives increases impairment unpredictably.
- Secure your environment. Do not drive or operate machinery. Have a sober companion available, especially for early experiences.
Set & Setting
As with all cannabinoids, psychological state and physical environment shape the experience. First-time users or those switching from conventional THC products should approach THCB with the same caution given to an unfamiliar cannabinoid — the partial agonist ceiling does not eliminate the risk of anxiety or paranoia, particularly at higher doses.
A calm, familiar environment with trusted company reduces the likelihood of adverse psychological responses.
Aftercare & integration. Uncomfortable THCB experiences generally resolve within hours. Hydration, light food, and rest support recovery. If anxiety or paranoia were prominent, spending time in a calm environment and talking through the experience with a trusted person can help normalize the response.
Persistent anxiety, depersonalization, or mood changes lasting more than 48 hours after use warrant professional consultation. These reactions are uncommon with cannabinoids but are documented following high-dose or adverse experiences.
Recovery & Support
Cannabis-type dependence — irritability, insomnia, appetite changes, restlessness upon stopping — is possible with regular THCB use.[17] The partial agonist profile may reduce but does not eliminate this risk.
For those seeking to reduce or stop use, gradual tapering is generally better tolerated than abrupt cessation. No approved medications exist for cannabis use disorder; cognitive-behavioral therapy and motivational enhancement are the best-supported interventions.[17] SAMHSA's National Helpline (1-800-662-4357) provides free referrals.
Recovery resources, crisis lines, and support pathways → View all
Emergency Response
Recognizing an emergency: Most adverse THCB experiences involve uncomfortable but self-limiting anxiety and paranoia. Seek immediate help if the person shows signs of psychosis (loss of contact with reality, severe agitation, self-harm risk), chest pain, fainting, or seizure.
Immediate steps:
- Call emergency services if the person is unresponsive, seizing, experiencing chest pain, or at risk of harming themselves or others.
- Move the person to a quiet, safe space. Reduce stimulation.
- Reassure them calmly. Remind them the effects are temporary and caused by a substance.
- Do not leave them alone.
- Do not induce vomiting if the product was ingested orally.
What to tell the dispatcher: Name the substance (THCB / THC structural analog), estimated amount and time of use, current symptoms, and any other substances consumed. Good Samaritan laws in many jurisdictions protect callers from prosecution.
Legal Status[edit]
Δ9-Tetrahydrocannabutol is not specifically listed under the United Nations Convention on Psychotropic Substances.[19] Several jurisdictions control it under generic cannabinoid definitions that encompass alkyl homologs of THC. The legal landscape is shifting rapidly as regulators respond to the proliferation of designer THC analogs on consumer markets.[5]
| Jurisdiction | Classification | Key provisions |
|---|---|---|
| United Kingdom | Class B (controlled) | Covered under MDA 1971 generic text for THC alkyl homologs. ACMD confirmed in 2025 that THCB falls within existing Class B controls[20] |
| Czech Republic | Prohibited | Explicitly added to the prohibited substance list in July 2024citation needed |
| France | Controlled | Covered under ban on cannabinoids with benzo[c]chromene-type chemical nucleuscitation needed |
| Australia | Likely Schedule 8 (controlled) | Poisons Standard defines controlled tetrahydrocannabinols to include all alkyl homologs; THCB would fall within this definition[19]citation needed |
| United States | Legal grey area | Not explicitly scheduled under the CSA. Hemp-derived THCB may be argued as legal under the 2018 Farm Bill, but the DEA's position that synthetically derived tetrahydrocannabinols remain Schedule I creates significant uncertainty for semi-synthetic products. The Federal Analogue Act may apply if intended for human consumption |
| Canada | Not explicitly scheduled | CDSA Schedule II covers cannabis, THC, and analogs; potential analog liability as a THC homolog |
| Japan | Under monitoring | Forensic identification of THCB in consumer products documented since 2022[4] |
The United States presents the most complex picture. THCB derived from hemp (Cannabis sativa containing less than 0.3% Δ9-THC) may be argued as legal under the 2018 Agriculture Improvement Act. However, the DEA's position that synthetically derived tetrahydrocannabinols remain Schedule I — and that chemical conversion constitutes synthesis — creates significant uncertainty for semi-synthetic Δ8-THCB products. Several states have enacted additional restrictions on novel cannabinoids independent of federal scheduling.
Frequently asked questions
What is Tetrahydrocannabutol?
Tetrahydrocannabutol (THCB) is a naturally occurring minor phytocannabinoid and partial CB1 agonist with a butyl (C4) side chain, first isolated in 2020. It binds CB1 with THC-comparable affinity (Ki 15 nM) but produces a partial cannabinoid tetrad response in mice, suggesting reduced maximal efficacy.
How long does Tetrahydrocannabutol last?
Total duration by route of administration — Oral: 4 – 8 hours; Inhaled: 2 – 4 hours. Ranges vary with dose and individual factors; see the duration table for onset, peak, and after-effect phases.
Where can I find dosage information for Tetrahydrocannabutol?
Psychedex publishes a dosage table for Tetrahydrocannabutol on this page covering these routes of administration: oral. Dose values are presented only in that table, always alongside their route of administration.
What are dangerous combinations with Tetrahydrocannabutol?
The highest-severity documented interactions for Tetrahydrocannabutol: Benzodiazepines, Barbiturates (Dangerous), GHB, Baclofen (Dangerous), GHB, GBL (Dangerous), Ibogaine (Dangerous), Opioids (Dangerous). See the interactions section for the full list with mechanisms and severity levels.
Is Tetrahydrocannabutol addictive?
Psychedex records tolerance and dependence data rather than a yes/no rating. Recorded tolerance indicators for Tetrahydrocannabutol: tolerance builds moderate; full reset takes 21 days; cross-tolerance develops with Δ9-THC, Δ8-THC, THCP, THCV, THCH, synthetic cannabinoids. See the article's dependence and safety sections for recorded dependence data.
experience reports
No experience reports yet. Be the first to contribute.
First-person accounts of subjective effects, timing, and outcomes — submitted for harm reduction.
references
- [1] ^abcdefghijkLinciano P, Citti C, Luongo L, Belardo C, Maione S, Vandelli MA, Forni F, Gigli G, Laganà A, Montone CM, Cannazza G (2020) Isolation of a High-Affinity Cannabinoid for the Human CB1 Receptor from a Medicinal Cannabis sativa Variety: Δ9-Tetrahydrocannabutol, the Butyl Homologue of Δ9-Tetrahydrocannabinol — Journal of Natural Products doi:10.1021/acs.jnatprod.9b00876
- [2]
- [3]
- [4] ^abcTai S, Hyatt WS, Gu C, Franks LN, Vasiljevik T, Brents LK, Prather PL, Fantegrossi WE (2015) Repeated administration of phytocannabinoid Δ9-THC or synthetic cannabinoids JWH-018 and JWH-073 induces tolerance to hypothermia but not locomotor suppression in mice, and reduces CB1 receptor expression and function in a brain region-specific manner — Pharmacological Research doi:10.1016/j.phrs.2015.09.006
- [5] ^abcCitti C, Linciano P, Russo F, Luongo L, Iannotta M, Maione S, Laganà A, Capriotti AL, Forni F, Vandelli MA, Gigli G, Cannazza G (2019) A novel phytocannabinoid isolated from Cannabis sativa L. with an in vivo cannabimimetic activity higher than Δ9-tetrahydrocannabinol: Δ9-Tetrahydrocannabiphorol — Scientific Reports doi:10.1038/s41598-019-56785-1
- [6] ^Linciano P, Citti C, Russo F, Tolomeo F, Laganà A, Capriotti AL, Luongo L, Iannotta M, Belardo C, Maione S, Forni F, Vandelli MA, Gigli G, Cannazza G (2020) Identification of a new cannabidiol n-hexyl homolog in a medicinal cannabis variety with an antinociceptive activity in mice: cannabidihexol — Scientific Reports doi:10.1038/s41598-020-79042-2
references
- [1] ^abcdefghijklmnoLinciano P, Citti C, Luongo L, Belardo C, Maione S, Vandelli MA, Forni F, Gigli G, Laganà A, Montone CM, Cannazza G (2020) Isolation of a High-Affinity Cannabinoid for the Human CB1 Receptor from a Medicinal Cannabis sativa Variety: Δ9-Tetrahydrocannabutol, the Butyl Homologue of Δ9-Tetrahydrocannabinol — Journal of Natural Products doi:10.1021/acs.jnatprod.9b00876
- [2] ^abcdeCitti C, Linciano P, Russo F, Luongo L, Iannotta M, Maione S, Laganà A, Capriotti AL, Forni F, Vandelli MA, Gigli G, Cannazza G (2019) A novel phytocannabinoid isolated from Cannabis sativa L. with an in vivo cannabimimetic activity higher than Δ9-tetrahydrocannabinol: Δ9-Tetrahydrocannabiphorol — Scientific Reports doi:10.1038/s41598-019-56785-1
- [3] ^abLinciano P, Citti C, Russo F, Tolomeo F, Laganà A, Capriotti AL, Luongo L, Iannotta M, Belardo C, Maione S, Forni F, Vandelli MA, Gigli G, Cannazza G (2020) Identification of a new cannabidiol n-hexyl homolog in a medicinal cannabis variety with an antinociceptive activity in mice: cannabidihexol — Scientific Reports doi:10.1038/s41598-020-79042-2
- [4]
- [5]
- [6] ^abcTai S, Hyatt WS, Gu C, Franks LN, Vasiljevik T, Brents LK, Prather PL, Fantegrossi WE (2015) Repeated administration of phytocannabinoid Δ9-THC or synthetic cannabinoids JWH-018 and JWH-073 induces tolerance to hypothermia but not locomotor suppression in mice, and reduces CB1 receptor expression and function in a brain region-specific manner — Pharmacological Research doi:10.1016/j.phrs.2015.09.006